Biocon Biologics embarks on a three-stage strategic journey

Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries

Biocon Biologics Limited is commemorating its first anniversary as a fully integrated, global biosimilars company dedicated to expanding access to high-quality affordable biologic medicines for patients worldwide.

This marks the one-year milestone of Biocon Biologics’ emergence as a global enterprise operating in over 120 countries, supported by a diverse, multicultural workforce spanning more than 30 nationalities. With a robust commercial presence in key advanced and emerging markets, Biocon Biologics has moved closer to patients who rely on its high-quality biosimilars to manage their debilitating conditions. By ensuring business continuity throughout this complex transition, Biocon Biologics has built trust with patients, physicians, and payors across geographies and credibility as a reliable partner.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited said, “I am proud and excited to celebrate Biocon Biologics’ first-year anniversary as a truly multi-national, multi-cultural global enterprise. We have successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries. Having achieved several milestones and embraced new opportunities, we have laid a strong foundation for accelerated business growth that will unlock value for the company and all our stakeholders."

Biocon Biologics embarked on a three-stage strategic journey — Preserve, Consolidate, Accelerate. This approach led to the preservation of value during the business transition in 2023, followed by consolidation of the business in 2024 while achieving profitable growth. The company has now stepped into the final stage of accelerated business growth in 2025 and beyond.

Preserve (ensured business continuity): Following completion of the acquisition in November 2022, Biocon Biologics successfully navigated the complexities of integrating a global business which can often take 2-3 years and focused on preserving the value for all stakeholders. Through the seamless integration of people and the commercial engine, the company served its patients ensuring uninterrupted product supplies globally. The company retained its customers, secured critical regulatory approvals, and transferred market authorizations to ensure continuity of the business across 120+ countries.

Consolidate (surpassed $1 billion revenue milestone): The successful integration of the acquired business in December 2023, a year ahead of schedule and one of the fastest in the industry, allowed the company to focus on Consolidation. By March 2024, it surpassed the US $1 billion annual revenue milestone. It also achieved increased market shares for its products across geographies, reflecting strong customer confidence and recognition of its products and people. Leveraging its own field force and strategic partnerships, the Company expanded patient reach, and forged long-term, strategic commercial collaborations with the intent to serve more patients globally. In doing so, it was also able to unlock value in its product brands in several markets, including India.

Between January and December 2024, the company carried out over 60 product launches in emerging and advanced Markets. Successful regulatory inspections of its facilities in India unlocked opportunities for new product launches in the US YESAFILI, Biocon Biologics' bAflibercept, received approval in the US, Europe, and UK, while YESINTEK (bUstekinumab) received USFDA marketing authorization and a recommendation for approval from EMA’s CHMP.

Accelerate (year 2025 marks the beginning of a new phase): Biocon Biologics is now focusing on accelerating growth by launching new products in existing markets and introducing existing products to new territories. Over the next two to three years, it plans three global launches (bAflibercept, bUstekinumab, and bDenosumab) and five US launches (bAspart, bBevacizumab, bAflibercept, bUstekinumab, and bDenosumab). This accelerated growth aims to propel Biocon Biologics to be among the top 3 biosimilars companies globally.